CIA Director William Burns tests positive for Covid after meeting with Biden, but is not considered a close contact

CIA Director William Burns tests positive for Covid after meeting with Biden, but is not considered a close contact


CIA Director Bill Burns testifies next to Director of National Intelligence Avril Haines during a House (Select) Intelligence Committee hearing on diversity in the intelligence community, on Capitol Hill in Washington, October 27, 2021.

Elizabeth Frantz | Reuters

WASHINGTON – CIA Director William Burns tested positive for Covid-19 on Thursday, the intelligence agency said.

Burns, who is fully vaccinated and boosted against Covid-19, last met with President Joe Biden on Wednesday morning during a “socially distanced meeting and was wearing an N-95 mask.”

“Their interaction is not considered close contact as defined by CDC guidance, and Director Burns is sharing the news of his positive test out of an abundance of transparency,” the intelligence agency wrote in a statement.

Burns will continue to perform his duties as CIA director but will work from home. He will return to the office following a negative test and after isolating for five days. The agency said that Burns has experienced mild symptoms.

Burns’ positive test follows two other virus cases within Biden’s orbit.

On Sunday, White House deputy press secretary Karine Jean-Pierre said she tested positive for Covid-19. Her positive test result came several days after White House press secretary Jen Psaki tested positive for the virus, which prevented her from traveling with Biden to Belgium and Poland.

Psaki said at the time that Biden was not considered a close contact following two socially distanced meetings.

Earlier this month, second gentleman Doug Emhoff tested positive for Covid-19. Following the positive test result, the White House said that Vice President Kamala Harris would skip a scheduled event “out of an abundance of caution.”

Biden, 79, received his fourth dose of the coronavirus vaccine on Wednesday.



Source

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Health

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to cut drug prices, and threatens to impose sweeping tariffs on pharmaceuticals imported into the […]

Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Health

Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise

Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter. Bloomberg | Bloomberg | Getty Images Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, […]

Read More
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Health

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]

Read More